mergers & acquisitions

Jounce Therapeutics to Merge With Redx After Laying Off 57 Percent of Workforce

Aileron Therapeutics Nixes Chemoprotective Trial of ALRN-6924 in p53-Mutated Breast Cancer

Fusion Pharmaceuticals to Acquire Prostate Cancer Radiopharmaceutical Program From RadioMedix

Isoray, Viewpoint Molecular Targeting Complete Merger to Advance Targeted Radiopharmaceuticals

Indivumed Sells Biospecimens Service Unit to CRO Crown Bioscience

Leap Therapeutics Merges With Flame Biosciences to Advance Several Precision Oncology Drugs

Elicio Therapeutics to Merge With Angion Biomedica

Gilead Sciences to Acquire Cell Therapy Biotech Tmunity Therapeutics

Invitae Sells Archer NGS Research Assays to Integrated DNA Technologies for $48M

AstraZeneca to Acquire Cell Therapy Firm Neogene Therapeutics

Biocare Medical Acquires Empire Genomics

AUM Biosciences to Go Public via Merger With Mountain Crest Acquisition

Avacta to Acquire Dx Distributor Launch Diagnostics for up to £37M

Enliven Therapeutics, Imara Merge to Advance Precision Oncology Pipeline

Roche to Acquire Good Therapeutics for $250M

MDxHealth Acquires Prostate Cancer Testing Business From Exact Sciences for up to $100M

Ipsen Acquires Epizyme, Garners Tazverik, Other Oncology Assets

BMS to Acquire Turning Point Therapeutics in Deal Valued at $4.1B

Taiho Pharmaceutical Acquires Cullinan Pearl, Regaining Rights to EGFR Inhibitor